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Abstract
MicroRNAs are being exploited for diagnosis, prognosis and monitoring of cancer and other diseases. Their high tissue
specificity and critical role in oncogenesis provide new biomarkers for the diagnosis and classification of cancer as well as
predicting patients’ outcomes. MicroRNAs signatures have been identified for many human tumors, including colorectal
cancer (CRC). In most cases, metastatic disease is difficult to predict and to prevent with adequate therapies. The aim of our
study was to identify a microRNA signature for metastatic CRC that could predict and differentiate metastatic target organ
localization. Normal and cancer tissues of three different groups of CRC patients were analyzed. RNA microarray and
TaqMan Array analysis were performed on 66 Italian patients with or without lymph nodes and/or liver recurrences. Data
obtained with the two assays were analyzed separately and then intersected to identify a primary CRC metastatic signature.
Five differentially expressed microRNAs (hsa-miR-21, -103, -93, -31 and -566) were validated by qRT-PCR on a second group
of 16 American metastatic patients. In situ hybridization was performed on the 16 American patients as well as on three
distinct commercial tissues microarray (TMA) containing normal adjacent colon, the primary adenocarcinoma, normal and
metastatic lymph nodes and liver. Hsa-miRNA-21, -93, and -103 upregulation together with hsa-miR-566 downregulation
defined the CRC metastatic signature, while in situ hybridization data identified a lymphonodal invasion profile. We
provided the first microRNAs signature that could discriminate between colorectal recurrences to lymph nodes and liver
and between colorectal liver metastasis and primary hepatic tumor.
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Introduction
The main cause of death in cancer patients is metastatic disease
[1]. Cancer cells dissemination has been considered a late multi-
step event during tumor development. After the primary tumor
growth, genetically selected, malignant cells invade the local tissue,
enter to blood and/or lymphatic vessels, are transported to distant
sites and colonize new organ tissues. Recent evidences suggest that
tumor spread could be an earlier event that will eventually
manifest after several years from diagnosis [2–5].
Colorectal cancer is the third most common malignancy in the
developed world after lung and breast cancer: about half of the
patients die of metastatic disease within 5 years from diagnosis [6].
The first sites of metastatic disease of colorectal cancer are the
regional lymph nodes and the liver. Pathological examination of
colon adenocarcinoma can not accurately predict patients that will
have disseminated disease to local lymph nodes and/or to distant
sites. However, in colon, as well as in breast and melanoma cancer
patients, the presence or the absence of lymph nodes invasion can
influence the type of surgical resection or the type of chemother-
apy regime [7–9].
Although metastases to the liver often come from colon cancers,
there are cases where metastasis is the first and only finding in
patients with an unknown primary tumor site [10], and the
distinction between primary hepatic lesions and liver metastasis
from different possible sites is of therapeutic and prognostic value
[11].
Thus, there is an increasing need of novel diagnostic and
prognostic biomarkers that could discriminate between the
primary tumor and the different sites of metastasis, as well as
predicting the metastasizing propensity of the primary tumor.
MicroRNAs or miRNAs, are small (19–25 nucleotides) non
coding RNAs, that regulate genes expression by post-transcrip-
tionally suppressing mRNA translation, and/or causing mRNA
degradation. They are involved in the regulation of the majority of
physiological processes [12], and are aberrantly expressed in
tumor initiation and progression, predicting disease status and
clinical outcome [13,14]. Interestingly, microRNAs signatures are
highly tissue specific and can be used to classify cancers, and to
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identify the primary tumor of a metastatic lesion of unknown
origin [15–19].
The aim of our study was to identify a microRNA signature that
could allow differentiating between lymphonodal and hepatic
metastasis in patients with colo-rectal carcinoma.
Materials and Methods
Patient tissue samples
Three groups of patients were considered in the study (Table1).
Paraffin embedded tissues coming from 66 patients diagnosed
with colonic carcinoma were selected from the the University of
Rome ‘‘La Sapienza’’, UOC Anatomia ed Istologia Patologica C/
Cardiovascolare, tissue bank according to the TNM staging.
Out of 66 patients, 18 presented a primary colonic tumor with
no metastasis (Any T, N0, M0), 33 had colon cancer with lymph
nodes metastasis only (Any T, Any N, M0) and 15 were diagnosed
with colon cancer, lymph nodes and liver metastases (Any T, Any
N, M1). Separate tumor samples from the primary tumor, the
metastatic lymph nodes and the liver metastasis were collected for
each patient and processed for tissue microarray and TaqMan
Array MicroRNA Cards.
A second group of 16 patients coming from the files of the OSU
Pathology Department were enrolled in the study. For each
patient, normal colonic tissue, primary colonic adenocarcnoma,
metastatic lymph nodes and metastatic liver were analyzed, as well
as the corresponding normal lymph nodes and liver, when
available. The TMA that was generated from these patients
samples plus three sets of US Biomax Tissue arrays (BN05014 with
24 cases, BC05118 with 50 cases, CO702 with 69 cases) were used
for In Situ Hybridization(ISH). US Biomax cases represent the
third group of patients included in the study with normal adjacent
colonic tissues, primary colon adenocarcinoma with no lymph
node/distant metastases and primary colon cancer of patients with
documented lymph nodes and liver metastasis, and the actual
lymph node and/or liver metastases.
The project was approved by the Italian (Presidente - Prof. Aldo
ISIDORI, Prof. Lucio MIANO, Dott.ssa Amalia ALLOCCA,
Dott.ssa Enrica ARDUINI, Dott.ssa Maria CAPORALE, Prof.
Luciano CAPRINO, Dott.ssa Avia CARABELLI, Prof. Francesco
COGNETTI, Dott.ssa Anna DALLE ORE, Prof.ssa Marzia
DUSE, Dott.ssa Giuseppina DI GIAMMARCO, Dott. Domenico
Antonio IENTILE, Prof. Giovanni FABBRINI, Prof.ssa Paola
FRATI, Dott.ssa Maria Teresa LUPO, Prof. Franco MAN-
DELLI, Dott. Enrico MARINELLI, Dott.ssa Boza MAURO,
Prof. Paolo MENE’, Dott.ssa Elisabetta SIMONGINI, Prof. Pietro
SERRA, Prof. Giovanni SPERA, Dott. Ettore TIBERI, Avv.
Angelo TUZZA, Prof.ssa Annarita VESTRI, Prof. Vincenzo
ZIPARO) and American (http://orrp.osu.edu/irb/irbforms/)
Ethical Commettee (Prot.1119/13, Prot.2007E0748 respectively).
Specifically, both the Commettees, the Ohio State University
Institutional Research Board and il Comitato Etico ‘‘La
Sapienza’’, exempted us from patients informed consent since, in
both cases, paraffin embedded tissue were anonymously archived
samples, selected according to their TNM staging and patients
were not longer available.
RNA extraction
Total RNA was extracted processing five 20 mm thick sections
from each paraffin embedded tissue, using the RecoverAll Total
Nucleic Acid Isolation Kit (AMBION #1975) and following
manufacturer’s instructions.
Table 1. Patients grouping and TNM classification.
Assays Cases Patients TNM
RNA Microarray (I) 66 18 AnyT N0 M0
& 33 AnyT AnyN M0
TaqMan Array (II) 15 AnyT AnyN M1
RT-PCR (III) 16 16 AnyT AnyN M1
IV TMA
OSU TMA 16 16 Normal Colon
6 Normal Lymph Nodes
4 Normal Liver
16 Adenocarcinoma
10 Positive Lymph Nodes
12 Liver Metastasis
USBIOMAX TMA 24 21 Normal Colon
BN05014 3 Adenocarcinoma
USBIOMAX TMA 24 21 Normal Colon
BC05118
USBIOMAX TMA 68 3 Normal Colon
C0702 +1 marker 3 Normal Lymph Nodes
3 Normal Liver
30 Adenocarcinoma
24 Positive Lymph Nodes
5 Liver Metastasis
doi:10.1371/journal.pone.0096670.t001
Colon Metastatic MicroRNAs
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RNA labeling and hybridization on miRNA microarray chips
were performed as previously described [20]. Five mg of each
sample total RNA was hybridized on our miRNA microarray
(Ohio State Comprehensive Cancer Center, version 2.0), which
contains 460 mature miRNAs probes, spotted in quadruplicate
(235 Homo sapiens, 222 Mus musculus, and three Arabidopsis thaliana).
Different probes were used to recognize each mature miRNA and
most of the miRNAs precursors. Hybridization signals were
detected with Streptavidin Alexa Fluor 647 conjugates and
scanned images (Axon 4000B) were quantified using the Genepix
6.0 software (Axon Instruments). The same samples were also
analyzed with RT-PCR cards (Applied Biosystems).
miRNA microarray
Microarrays were essentially analyzed as described by Liu et al
[21]. Quantiles normalization and statistical analysis was per-
formed using BRB ArrayTools developed by Richard Simon and
Amy Peng Lam [22].
Differentially expressed miRNAs were identified using a
random-variance t-test. The random-variance t-test is an im-
provement over the standard separate t-test as it permits sharing
information among genes about within-class variation without
assuming that all genes have the same variance. Genes were
considered statistically significant if their P-value was lower than
0.05. [23].
Multiple testing was controlled using false detection rate.
miRNA nomenclature was established according to the UCSC
Genome Browser (http://genome.ucsc.edu/) and the miRBase
(http://www.mirbase.org/); in case of discrepancies the miRBase
was followed.
Raw data are available on the GEO website (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc =GSE56350).
TaqMan Array MicroRNA Cards and Quantitative Real
Time PCR
Real Time PCR was performed using the TaqMan Array
Human MicroRNA panel (v.1, Applied Biosystems, Foster City,
CA) and 50 ng of RNA per port for a total of 400 ng. This array
contains 365 miRNA targets as well as endogenous controls.
Normalization was performed with small nuclear RNAs (snRNA)
U44 and U48. Expression of single mature miRNAs was assessed
by the TaqMan miRNAassay (Applied Biosystems, Foster City,
CA, USA), and normalized to RNUB6 (Applied Biosystems). Raw
data are available on the GEO website (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc =GSE56350).
In situ hybridization
In situ hybridization was performed for selected microRNAs
following a previously described protocol [24], using Exiqon LNA-
5’DIG labeled probes. Three USBiomax tissue microarrays
(TMA) slides (Colon normal Tissue array with 21 normal cases
and 3 adenocarcinoma cases, Colon cancer and matched adjacent
normal tissue array with 25 cases, Colon cancer tissue array with
metastasis and adjacent normal tissue with 68 cases) and a slide
with tissue cores from 16 patients (OSU TMA) were used. For
each selected microRNA, TMAs were scored according to the
relative microRNA expression of each core by two pathologists as
defined by the percentage of positive tumor cells and the strength
of the signal in these cancer cells in positive cases. The scores were
generated blinded to the presence or absence of metastatic disease
and the Mann-Whitney test was applied to compare classes.
Results
Our study was developed in four steps by taking advantage of:
(I) DNA Microarrays, (II) Taqman high density cards, (III)
Taqman single assay qRT-PCR and (IV) in situ hybridization. To
achieve more robust results, we used three different groups of
patients (Table 1). The first group included 66 Italian patients (III
Clinica Chirurgica, Universita’ di Roma ‘‘La Sapienza’’, Rome,
Italy) with colonic adenocarcinoma: 18 patients did not have any
metastasis, 33 had affected lymph nodes and 15 showed metastases
at both lymph nodes and liver. Total RNAs from 18 colonic
primary tumors (T) with no metastasis, 33 colonic primary tumors
(TN) with lymphonodal recurrences and the corresponding 33
metastatic lymph nodes (NN), 15 colonic primary tumors (TL,) of
patients with lymphonodal and hepatic metastatic disease and the
corresponding 15 metastatic lymph nodes (NL) and liver lesions
(L), were tested on the custom microarray platform that had been
previously used to establish cancer microRNA signatures in several
studies [13,14,21], and on Taqman Array microRNA Cards
(Applied Biosystems). Data were normalized according to the
platform requirements and the same comparisons among classes
were applied to both the datasets separately. Significantly altered
miRNAs were identified and results were intersected. Only
microRNAs with a fold change difference larger than 2 or lower
than 0.5 were considered as the putative pro-metastatic and anti-
metastatic miRNAs respectively. Twelve microRNAs were con-
sistently up-regulated in metastasis (hsa-miR-103, -155, -16, -191,
-200c, -21, -24, -26a, -26b, -29a, -31 and 93) and only two were
down-regulated (hsa-miR-328 and -566) (Table 2).
The double array strategy allowed us to test the same samples
with two different technical approaches.
To further confirm the identified ‘‘metastatic’’signature, selected
microRNAs were tested on sixteen American patients with
metastatic colon cancer (OSU Pathology Dept., Columbus,
OH). For each patient, total RNA of paraffin embedded tissue
cores of normal and malignant colon, lymph node and liver, was
assayed by single qRT-PCR. The Mann-Whitney test was applied
to compare the PCR results from the different patient groups.
Primary metastatic colonic adenocarcinomas showed a signif-
icant overexpression of hsa-miR-21 (P-value = 0.0011), -31 (P-
value = 0.0003), -93 (P-value = 0.0048), -103 (P-value = 0.0142)
and downregulation of hsa-miR-566 (P-value = 0.0075) when
compared to their adjacent normal tissue (Table 2). Moreover,
respect to normal, hsa-miR-21 and -93 were significantly
upregulated in liver metastasis with a P-value = 0.020 and P-
value = 0.0002 respectively. Hsa-miR-21 was also significantly
overexpressed in metastatic lymph nodes (P-value = 0.009) (Fig.1).
These five validated microRNAs did not correlate with tumor
staging.
In tumors, the inflammatory and stromal cells are scattered
among benign and malignant epithelial cells, and variably
contribute to the cellularity of the lesion. It is, thus, essential to
understand which type of cell expresses a specific microRNA. For
this purpose, in situ hybridization experiments were carried out on
TMAs with primary adenocarcinomas, metastatic lymph nodes,
hepatic metastasis and normal tissues. Hsa-miR-21, -93, -103 and -
566 probes were hybridized onto OSUTMA and USBiomax TMA
slides. Two independent pathologists scored each slide core blinded
to the site of the core biopsy and to the clinical staging history,
considering the signal intensity of colonic malignant cells compared
to the adjacent normal epithelial and non-epithelial cells (Fig.2).
Hsa-miR-21 (P-value ,0.0001) and -103 (P-value = 0.0009) were
significantly over-expressed in adenocarcinomas and metastatic
cancers when compared to normals (Fig.2: A, B). A Chi-squared test
Colon Metastatic MicroRNAs
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revealed a linear trend for both, hsa-miR-21 (P-value,0.0001) and
hsa-miR-103 (P-value,0.0001): they were increasingly upregulated
progressing from normal, to adenocarcinoma and to metastasis
(Fig.3, Fig 4). However, while hsa-miR-103 was significantly
overexpressed in liver metastasis when compared to adenocarcino-
mas and positive lymph nodes, hsa-miR-21 did not show any
significant difference among the three classes. ISH of hsa-miR-93
confirmed its upregulation in adenocarcinomas and liver metastasis,
showing a significant difference between normals and either
adenocarcinomas (P-value = 0.0345) or liver metastasis (P-value
= 0.007) and between adenocarcinomas and liver metastasis (P-
value = 0.043). No significant difference was found when compar-
ing normals and adenocarcinomas versus positive lymph nodes (Fig.
2C and Fig.5). Thus, hsa-miR-93 expression pattern could
differentiate normal colon from primary adenocarcinoma, and
normal colon and primary adenocarcinoma from liver metastasis,
but not from secondary tumoral lymphnodal invasion. Hsa-miR-
566 was equally overexpressed in normal adjacent colonic tissue,
primary adenocarcinoma malignant cells and liver colonic meta-
static cells (Fig. 2D). However, positive lymph nodes showed a
significantly weaker signal in respect to the normals (P-value
= 0.002) and adenocarcinoma (P-value = 0.043), suggesting that
loss of hsa-miR-566 may facilitate lymph node invasion in colon
cancer.
Induction of Epithelial-to-Mesenchimal Transition (EMT) has
been considered an important step in the development of
Table 2. Experimental procedure and miRs signatures.
Assay Upregulated Has-MiRs Downregulated Has-MiRs
RNA Microarray & 103, 155, 16, 19, 200c, 21, 328, 566
TaqMan Array 24, 26a, 26b, 29a, 31, 93
RT-PCR 103, 21, 31, 93 566
TMAs 103, 21, 93 566
doi:10.1371/journal.pone.0096670.t002
Figure 1. qRT-PCR Box-Plots. Normal colon tissue (NORM), colon adenocarcinomas (ADENOCA), lymphonodal metastasis (POSLYM) and colon
liver (LIVERMET) for miR-21(A), miR-31 (B), miR-93 (C), miR-103 (D) and miR-566 (E). A Mann-Whitney test was applied to compare groups. Groups are
shown on the boxplots’ x-axis, while the delta Ct Values are represented on the y-axis. For each box, the bar represent the Median, the area the 25th
and 75th percentile and the whiskers of the graph the largest and smallest values. Each P-value bar correspond to a comparison: for each miR the first
lower bar refers to the NORM vs ADENOCA comparison; miR-21 second lower bar P-value corresponds to the NORM vs POS LYMPH comparison, while
the first upper bar of both miR-21 and -93 corresponds to the NORM vs LIVER MET comparison.
doi:10.1371/journal.pone.0096670.g001
Colon Metastatic MicroRNAs
PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e96670
metastatic cancer. Recently, it has been demonstrated that hsa-
miR-103/107 indirectly downregulates miR-200 family members,
and that such pattern is associated with mesenchymal phenotype
in breast cancer cell lines [24].
In our study, the microarray platform and Taqman assay,
isolated both hsa-miR-103 and hsa-miR-200c. We wanted to
understand whether, as in breast metastatic cancer, these two
miRNAs were inversely correlated in colon metastatic cancer.
Although not significant by qRT-PCR, TMAs were hybridized
with hsa-miR-200c probe and scored (Fig. 2E). Compared to
normals, a higher signal intensity was detected in adenocarcino-
mas (P-value = 0.0023) and positive lymph nodes (P-value
= 0.0006). A significant positive correlation between hsa-miR-103
and hsa-miR-200c was present in lymph node metastasis (P-value
= 0.0225), but not in adenocarcinomas or liver metastasis.
Therefore, hsa-miR-103 and hsa-200c were not inversely corre-
lated and do not regulate EMT in metastatic colon cancer in vivo,
but were both overexpressed in adenocarcinomas and lymph
nodes metastasis. We did not investigate hsa-miR-107 or any other
members of the miR-200 family because EMT was not relevant to
the aim of our study.
Interestingly, hsa-miR-31 ISH (data not shown) revealed a very
strong signal in inflammatory cells surrounding the tumors. A
weaker staining was observed in tumor and normal colonic cells,
but only few hsa-miR-31 expressing lymphocytes were present in
normal lymph nodes, suggesting that hsa-miR-31 upregulation
resulted mostly from the inflammatory rather than from the
malignant component of the tumor.
Table 1 reports the number of cases with TNM staging that
were analyzed at each technical step of our study; Table 2 shows
the microRNA signatures obtained with each technical procedure.
Discussion
The 2009 AJCC edition has published a new colon cancer
TNM classification, in which, subclasses have been added to the
(N) nodal disease staging. Other authors have proposed to replace
these N categories with the number of positive lymph nodes, and
several surgical publications have suggested a more radical
lymphadenectomy to better define prognosis in order to improve
colon cancer patients survival [26–29]. Nodal invasion is a critical
step for defining colon cancer patients prognosis and therapy.
However, 25% of lymph node-negative patients experience
recurrence and not all patients with positive lymph nodes have a
poor prognosis [30–32].
On the other hand, primary tumor spread to the liver, is the
major cause of disease progression in colorectal cancer patients,
with 15–30% of patients presenting with synchronous hepatic
Figure 2. TMA Box-Plots. with normal colon tissue (NORM), colon adenocarcinomas (ADENOCA), lymphonodal metastasis (POSLYM) and colon
liver (LIVERMET) for miR-21 (A), miR-103(B), miR-93(C), miR-566(D) and miR-200c(E). A Mann-Whitney test was applied to compare groups. Groups are
shown on the boxplots’ x-axis, while the average score Values are represented on the y-axis. For each box, the bar represent the Median, the area the
25th and 75th percentile and the whiskers of the graph the largest and smallest values. Each P-value bar correspond to a comparison: for miR-21,-103,
-93, and -200c the first lower bar corresponds to the NORM vs ADENOCA comparison; miR-21,-103, and -93 first upper bars refer to the NORM vs
LIVER MET comparison, while miR-566 and -200c upper bar shows the NORM vs POS LYMPH comparison; miR-566 and miR-200c lower bars indicate
the ADENOCA vs POS LYMPH and the NORM vs POS LYMPH comparison respectively.
doi:10.1371/journal.pone.0096670.g002
Colon Metastatic MicroRNAs
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lesions at the time of primary colorectal surgery, and, showing
metachronous recurrences after aggressive liver resection [33–35].
Thus, it is essential to identify new molecular biomarkers that,
together with the TNM staging system, can improve the diagnosis
and classification of metastatic colon cancer patients.
The aim of this study was to identify a microRNA signature for
metastatic colon cancer that could discriminate between lymph
nodes and liver metastasis.
In literature, most of the reported microRNAs cancer signatures
have been identified and validated on the same tissue samples. To
increase the reliability of our data, with the exception of the first
two analyses, each validation step was performed on a different
group of patients.
Microarray and cards platforms intersected data identified
fourteen differentially expressed microRNAs, of which five were
validated by qRT-PCR. Hsa-miR-21, -31, -93, -103 were
upregulated in primary tumors compared to normal, whereas
hsa-miR-566 was downregulated. Hsa-miR-93 and -31 were also
upregulated in liver metastasis, but not in lymph nodes positive for
metastasis, whereas hsa-miR-21 over-expression was evident in
both, liver and lymph nodes metastasis. With the exception of hsa-
miR-31, in situ hybridization (ISH) of colonic adenocarcinomas
and the corresponding adjacent normal tissue, as well as its nodal
and liver metastasis tissue microarrays, confirmed the signatures
identified by the cards and qRTPCR analyses. Hsa-miR-31 has
been found dysregulated in several primary epithelial tumors
where, according to tumor localization, it seems to trigger different
cancer pathways: it is up-regulated in some carcinomas [36–41],
and down-regulated in others [42–45]. Such a duality, has been
found in invasive tumors as well: in colon cancer cell lines,
invasion is promoted by hsa-miR-31 overexpression [46,47],
while, in breast cancer cell lines, its low levels promote a more
aggressive behavior [42], which correlates to a poorer patient
prognosis.
Targeted functions of hsa-miR-31 include angiogenesis, where
its upregulation increases blood, but not lymphatic vessels
sprouting [48], and acute inflammation [49]. We found that
hsa-miR-31 is mostly up-regulated in peritumoral inflammatory
cells, compared to cancer and normal cells. Thus, hsa-miR-31
dysregulation in primary aggressive tumors is an indisputable
evidence, but the interplay of its functions between the inflam-
matory, neoangiogenic and tumoral metastatic context, needs, still,
to be elucidated.
Hsa-miR-21 is another multitask microRNA that has been
implicated in inflammation [50–53], immune disease [54–57],
development [58–61], angiogenesis [62,63], cancer and metastasis
[18,64–82]. Several studies have, in fact reported its over-
expression in different type of tumors, including colorectal
carcinoma, where its levels correlate to clinical progression, poor
survival and therapeutic outcome [83,84].
Figure 3. miR-21 In Situ Hybridization of Normal Colon (5X), Primary Tumor (5X) and Liver Metastasis (Different magnifications: 5X,
10X, 20X). As documented in literature, miR-21 showed a weak signal in normal colon respect to adenocarcinoma (P-value = 0.0011) and it was
highly expressed in metastasis. MiR-21 expression was detected only in primary adenocarcinoma and metastatic malignant cells.
doi:10.1371/journal.pone.0096670.g003
Colon Metastatic MicroRNAs
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In agreement with our previous studies and those of others,
qRT-PCR validated hsa-miR-21 upregulation in colonic adeno-
carcinomas and metastasis when compared to normal. In situ
hybridization data showed a trend: hsa-miR-21 levels were the
lowest in normal tissue, and increasingly higher in adenocarcino-
ma and metastasis, meanwhile, a similar expression was observed
in cancer cells nodes and liver recurrences, suggesting that hsa-
miR-21 upregulation could predict an advanced metastatic
disease.
As with hsa-miR-31, high levels of hsa-miR-21 and -93 have
been described by other authors in hepatocellular carcinoma
[39,85,86] and, therefore, they can not be considered as a
diagnostic differential signature between liver metastasis and
hepatocellular carcinoma.
The ISH data for hsa-miR-93 completely overlapped the qRT-
PCR results: an intense staining was detected in primary colonic
adenocarcinomas and liver metastasis. Induced over-expression of
hsa-miR-93 was shown: to be tumorigenic in vitro and in vivo, to
promote survival but not proliferation, and to enhance neoangio-
genesis [87]. Moreover, increased hsa-miR-93 levels, correlate to
progression and decreased patients survival in serous ovarian
carcinoma [88] and, can predict relapse breast cancer [89].
However, the only up-regulated validated microRNA identified
in our signature that could discriminate between colonic hepatic
metastasis and primary hepatocellular carcinoma was hsa-miR-
Figure 4. miR-103 In Situ Hybridization of Normal Colon (5X), Primary Tumor (5X), Normal Liver (5X), Liver Metastasis (5X, 10X) and
Metastatic Lymph node (5X). In normal colon the arrow is pointing at the lack of miR-103 expression in epithelial cells. In the primary tumor the
arrow is pointing at the increased expression of miR-103 in the invasive adenocarcinoma. The arrow in liver recurrence and the two arrows in the
lymph node metastases are showing a dramatic increased expression of miR-103 in the metastatic adenocarcinoma epithelia.
doi:10.1371/journal.pone.0096670.g004
Figure 5. miR-93 In Situ Hybridization of Normal Colon (5X), Primary Tumor (5X) and lymph node metastasis (5X).
doi:10.1371/journal.pone.0096670.g005
Colon Metastatic MicroRNAs
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103. The relevance of this miRNA in cancer has been assessed in
pancreatic, bladder, esophageal, gastric and breast tumors [29,90–
93]. High levels of hsa-miR-103 were correlated to poor survival in
esophageal cancer and are associated to metastatic disease in
breast and gastric cancer. Particularly, hsa-miR-103 upregulation
was detected in gastric cancer patients bearing positive lymph
nodes. Similarly, in our study, qRT-PCR detected hsa-miR-103
over-expression in primary tumors as well as metastatic nodes and
liver. Again, ISH gave us more specific cell-of-origin information:
while, there were no significant differences between primary
tumors and positive lymph nodes, liver metastasis showed the
highest levels of hsa-miR-103 expression.
In our study, although not validated by qRT-PCR, hsa-miR-
200c was one of the selected microRNA by microarray and cards
platforms. Recently, hsa-miR-103/107 levels were found inversely
correlated to hsa-miR-200c in the regulation of Epithelial-to-
Mesenchimal Transition in breast cancer [25]. To test if we could
establish the same correlation in colon cancer, we performed ISH
of colon TMA with miR-200c probe. We did not observe any
inverse correlation between the two miRNAs. They were both
over-expressed, but, hsa-miR-200c was strongly up-regulated in
lymph nodal metastasis compared to normal colon, adenocarci-
nomas and liver recurrences. This suggests that hsa-miR-103 and
hsa-miR-200c do not control EMT in colon cancer, and that high
levels of hsa-miR-200c are required for nodal invasion.
Hsa-miR-200c liver metastasis ISH scores showed high
variability, covering the average values of normal tissue, adeno-
carcinomas, and positive lymph nodes. Downregulation of hsa-
miR-200c has been proposed as a distinctive signature of primary
liver cancer (hepatocellular carcinoma, intrahepatic cholangiocar-
cinoma and hepatic angiosarcoma) from liver metastasis of
epithelial origin [86,94], while its upregulation in colon adeno-
carcinoma has been associated to a poor prognosis [95]. In our
study, hsa-miR-200c upregulation in nodal metastasis was
confirmed by ISH, but was not validated by qRT-PCR. This
finding is due mainly to experimental and technical procedures.
First, we used different groups of patients for validation, which,
although providing more reliable end data, introduced more
variability into the experimental procedure. Second, RNAs
coming from our first microarrays patient group, were not
extracted from microdissected paraffin embedded tissues and
contained variable proportions of cancer and benign surrounding
tissue, while the RNAs and tissues analyzed in the qRT-PCR and
ISH were tissue microdissected cores with a major cancer
component. However, qRT-PCR cannot differentiate from benign
and/or non cancer cells, whereas ISH can discriminate among the
different types of cells. Other authors validated their data on the
same patients, and RNA was extracted from the whole tissue.
Moreover, to the best of our knowledge, in literature there is no
study reporting such a large scale of microRNA ISH. We have
demonstrated that ISH can provide very useful cell specific
information, suggesting additional microRNAs in vivo functions for
further investigations.
An important novelty of our signature was hsa-miR-566.
Apparently down-regulated only in adenocarcinomas with respect
to controls and metastatic colonic tissues by qRT-PCR, hsa-miR-
566 digoxigenin labeled probe, was weakly detected in positive
lymph nodes cancer cells, and equally expressed in normal colon,
as well as adenocarcinomas and liver metastasis, supporting the
notion that ISH can give us more informative details than
microarrays or qRT-PCR. Unfortunately, in literature, there is no
study reporting hsa-miR-566 involvement in cancer, or describing
its biological functions, that could aid the discussion of our data.
We can only state that hsa-miR-566 was down-regulated in nodal
colon metastatic cancer.
Several microRNA signatures based on clinical outcomes, have
been identified to predict prognosis, but, so far, none of them has
reported a distinctive pattern between nodal and liver recurrences.
We identified a colon metastatic signature that can discriminate
between lymph nodes and liver metastasis. High levels of hsa-miR-
21, -93 and -103 characterized liver metastasis, and thus, a more
advanced metastatic disease, whereas, an over-expression of hsa-
miR-200c coupled with low levels of hsa-miR-566, could be able
to detect nodal invasion. Future stratified studies need to be
conducted in order to ratify and correlate our signature to
prognostic clinicopathologic factors.
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